Beneficial effects of silibinin on serum lipids, bile acids, and gut microbiota in methionine-choline-deficient diet-induced mice

Wei Wang, Ting Zhai, Ping Luo, Xiaolei Miao, Junjun Wang, Yong ChenFrontiers in Nutrition 2023 · DOI

TL;DR

This study investigates the therapeutic potential of silibinin (SIL), a compound from milk thistle, in a mouse model of non-alcoholic steatohepatitis (NASH). The research reveals that SIL effectively improves liver health by modulating gut microbiota, normalizing bile acid profiles, and rebalancing serum lipid levels, suggesting SIL could be a promising dietary supplement for NASH prevention.

What Problem Does This Paper Address?

Nonalcoholic fatty liver disease (NAFLD), progressing to non-alcoholic steatohepatitis (NASH), is a growing global health concern characterized by liver steatosis, inflammation, and potential fibrosis. While the exact mechanisms are complex, accumulating evidence points to the crucial roles of lipid metabolism, bile acid (BA) homeostasis, and gut microbiota (GM) dysbiosis in its pathogenesis. Current treatments are limited, highlighting the need for novel therapeutic strategies. Silibinin (SIL), a flavonoid from Silybum marianum, has shown promise in preclinical studies for liver protection, but its specific effects on the interconnected pathways of lipids, BAs, and GM in NASH remain largely unexplored. This paper aims to bridge this knowledge gap by investigating how SIL supplementation impacts these key factors in a methionine-choline-deficient (MCD) diet-induced NASH mouse model.

Methods

The researchers employed a multi-omics approach to comprehensively assess the effects of SIL.

  • Animal Model: Male C57BL/6 mice were fed a methionine-choline-deficient (MCD) diet for 8 weeks to induce NASH. A control group received a normal diet (MCS). A separate group was treated with silibinin (SIL) at 20 mg/kg/day, and another with obeticholic acid (OCA) as a positive control.
  • Histopathology: Liver tissues were stained with Oil Red O, Hematoxylin-Eosin (HE), and Masson's trichrome to evaluate lipid deposition, cellular damage, and fibrosis.
  • Biochemical Analysis: Serum levels of liver injury markers (ALT, AST) and liver tissue levels of triglycerides (TG) and malondialdehyde (MDA) were measured using assay kits.
  • Lipidomics: Untargeted liquid chromatography-mass spectrometry (LC-MS) was used to analyze the composition and relative abundance of serum lipids. Multivariate statistical analysis (PCA, OPLS-DA) and KEGG pathway enrichment analysis were performed to identify differential lipids and metabolic pathways.
  • Bile Acid Analysis: Targeted LC-MS was employed to quantify the levels of 50 different bile acids in serum.
  • Gut Microbiota Sequencing: 16S rDNA sequencing of ileal contents was performed to analyze the diversity and composition of the gut microbiota.
  • Gene Expression Analysis: RT-qPCR was used to measure the mRNA expression levels of key hepatic genes involved in bile acid metabolism and transport (CYP7A1, CYP27A1, Bsep, Mrp2, Ntcp, Oatp1b2).
  • Statistical Analysis: Standard statistical methods, including t-tests and one-way ANOVA, were used. Spearman correlation analysis was employed to investigate the relationships between gut microbiota and serum lipid/bile acid levels.

Datasets

The study utilized serum and liver tissue samples from mice in four groups: normal control (MCS), NASH model (MCD), SIL-treated NASH (SIL), and OCA-treated NASH (OCA). The primary datasets generated were:

  • Serum lipidomics data.
  • Serum bile acid profiles.
  • 16S rDNA sequencing data of gut microbiota.
  • mRNA expression data from liver tissues.

No new public benchmarks were introduced.

Key Insights and Ideas

  • SIL's Multifaceted Impact: The study highlights that SIL doesn't just target one aspect of NASH but exerts beneficial effects across multiple interconnected systems: liver pathology, serum lipids, bile acids, and gut microbiota. This suggests a holistic therapeutic mechanism.
  • Gut Microbiota as a Key Mediator: A central finding is that SIL's beneficial effects are strongly linked to its ability to modulate gut microbiota composition. Specifically, the increase in beneficial bacteria like Akkermansia muciniphila appears to be a critical driver for improving lipid and bile acid profiles.
  • Enterohepatic Axis Regulation: The research proposes that SIL influences the enterohepatic axis—the bidirectional communication between the liver and the gut—by altering gut microbiota, which in turn regulates serum lipids and bile acids. This is a significant insight into how dietary compounds can impact liver health.
  • Bile Acid Rebalancing: SIL treatment helped normalize the levels of certain bile acids, reducing potentially harmful ones while increasing beneficial ones, contributing to liver protection.
  • Lipid Profile Improvement: SIL effectively reduced the levels of harmful lipids in the serum, moving the lipid profile closer to that of healthy control mice.

Key Results

  • Liver Histopathology: SIL treatment significantly improved liver histopathology in MCD mice, reducing lipid droplet accumulation and disordered liver cell arrangement compared to the MCD group.
  • Biochemical Markers: SIL significantly reduced serum ALT and liver TG and MDA levels in MCD mice, indicating a reduction in liver injury and oxidative stress.
  • Serum Lipids: SIL treatment led to a decrease in the levels of 26 specific lipids (including arachidonic acids, FFAs, acyl carnitines, and GPs) and an increase in 10 lipids (including TGs and GPs) in MCD mice, shifting the profile towards that of the control group.
  • Serum Bile Acids: SIL treatment significantly altered bile acid profiles, increasing levels of β-MCA, α-MCA, UDCA, 3-oxo-DCA, and HCA, while decreasing 23-norDCA and GLCA compared to the MCD group.
  • Gut Microbiota: SIL significantly increased the abundance of Verrucomicrobiota (specifically Akkermansiaceae and Akkermansia) in the ileum of MCD mice. Conversely, it reduced the abundance of Dubosiella.
  • Gene Expression: SIL treatment did not significantly alter the mRNA expression of key hepatic bile acid metabolism and transport genes (CYP7A1, CYP27A1, Bsep, Mrp2, Ntcp, Oatp1b2) in the liver, reinforcing the idea that its effects are mediated through the gut-liver axis rather than direct hepatic gene regulation.
  • Correlations: Akkermansia abundance was negatively correlated with harmful lipids (oxidized lipids, certain ACs, FFAs, GPs) and certain bile acids (UDCA, 3-oxo-CA, 23-norDCA), while Dubosiella showed opposite correlations, supporting its role as a mediator.

Limitations and Future Work

  • Hepatic Gene Expression: The lack of significant changes in the expression of key hepatic BA metabolism genes suggests that SIL's primary mechanism in this context is not direct hepatic regulation but rather indirect modulation via the gut-liver axis. This warrants further investigation into the specific signaling pathways involved.
  • Thermogenesis: The study noted that KEGG pathway enrichment analysis of differential lipids identified thermogenesis as a related pathway. The authors suggest that the effect of SIL on brown and beige fat thermogenesis and its connection to NASH warrants further investigation.
  • Dubosiella's Role: While SIL reduced Dubosiella abundance, the paper acknowledges that the precise role of Dubosiella in NASH and its relationship with SIL requires further study.
  • Ceramide Levels: The study found no significant changes in most serum ceramide levels, except for one specific ceramide, and suggests this difference might be due to variations in diet composition (MCD vs. HFD) used in other studies.
  • Long-term Effects: The study was conducted over 8 weeks. Investigating the long-term effects of SIL supplementation on NASH progression and its impact on other metabolic parameters would be valuable.
  • Human Translation: While promising, these findings are from a mouse model. Clinical trials are necessary to confirm SIL's efficacy and safety in humans with NASH.

Summary updated

Abstract

The alleviating effect of SIL on NASH may be closely related to the correction of intestinal bacteria disorder, serum bile acid, and lipid metabolic disturbance in mice.
BibTeX
@inproceedings{wang2023beneficial,
  author = {Wei Wang and Ting Zhai and Ping Luo and Xiaolei Miao and Junjun Wang and Yong Chen},
  title = {{Beneficial effects of silibinin on serum lipids, bile acids, and gut microbiota in methionine-choline-deficient diet-induced mice}},
  booktitle = {Frontiers in Nutrition},
  year = {2023},
  doi = {10.3389/fnut.2023.1257158},
}
Figure